Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 500 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/500 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate; salmeterol as xinafoate - powder for inhalation - fluticasone propionate 250 mcg; salmeterol as xinafoate 50 mcg - salmeterol and other drugs for obstructive airway diseases - salmeterol and other drugs for obstructive airway diseases - seretide is indicated in the regular treatment of asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) has been found to be appropriate. seretide (50/250 mcg) is indicated for the symptomatic treatment of patients with copd, with a fev1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.

Canada - English - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - powder - 50mcg; 100mcg - salmeterol (salmeterol xinafoate) 50mcg; fluticasone propionate 100mcg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - powder - 50mcg; 250mcg - salmeterol (salmeterol xinafoate) 50mcg; fluticasone propionate 250mcg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - powder - 50mcg; 500mcg - salmeterol (salmeterol xinafoate) 50mcg; fluticasone propionate 500mcg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - aerosol, metered dose - 25mcg; 125mcg - salmeterol (salmeterol xinafoate) 25mcg; fluticasone propionate 125mcg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

glaxosmithkline inc - salmeterol (salmeterol xinafoate); fluticasone propionate - aerosol, metered dose - 25mcg; 250mcg - salmeterol (salmeterol xinafoate) 25mcg; fluticasone propionate 250mcg - selective beta 2-adrenergic agonists

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluticasone propionate, quantity: 125 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. evocair is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.